Hypertension-related kidney disease will progress in most black patients even when they have been treated with the best available therapy, according to results from a large cohort study that was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (Appel LJ et al. Arch Intern Med. 2008;168:832-839).
The study involved about 750 black individuals with hypertensive renal disease from the African-American Study of Kidney Disease and Hypertension, all of whom were treated with the currently recommended therapy of angiotensin-converting enzyme inhibitors to systolic and diastolic blood pressures of lower than 130 and 80 mm Hg, respectively. Nearly 54% (567 participants) experienced a doubling of their serum creatine level, developed end-stage renal disease, or died, while only one-third experienced a slow decline in kidney function resembling that seen in normal aging.
Kuehn BM. Kidney Disease in Blacks. JAMA. 2008;299(24):2847. doi:10.1001/jama.299.24.2847-c